Tag: Alzheimer’s disease
AI as a Diagnostic Tool
Using AI systems for pattern recognition in early diagnosis of dementia shows the potential of this tool.
Congress criticizes the FDA and the Aduhelm approval
A Congressional report on the approval of the Alzheimer's drug Aduhelm identified serious concerns about the FDA's processes
Another Controversial Alzheimer’s Drug
A new treatment for Alzheimer's Disease is promising, but we're not there yet.
Can supplements improve memory and cognition?
Can you reduce the risk of cognitive decline with dietary supplements?
Fraud, Scientific Rigor, and Alzheimer’s Research
A stunning case of possible fraud in Alzheimer's research reinforces the need for scientific rigor at every level.
COVID Associated With Neurodegenerative Disorders
COVID infection has been associated with an increased risk of neurodegenerative and neurovascular disease - another reason to keep our eye on this serious illness.
Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)
An important decision has been made about a controversial new drug to treat Alzheimer's disease.
Poor Science Reporting and Premature Enthusiasm
Press releases often outpace the data. Here are some examples of over-enthusiastic reporting on extremely preliminary research.
FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s
Criticism of the FDA's decision to approve aducanumab for Alzheimer's disease.
No evidence, no problem: A closer look at the aducanumab approval
Why did the FDA approve aducanumab, a drug that hasn't been shown to work?